Equities Analysts Offer Predictions for TNXP FY2025 Earnings

Key Points

• Zacks Small Cap raised its FY2025 EPS estimate for Tonix to ($13.20) from ($14.01) and also projects negative EPS for Q4 2025, FY2026 and FY2027; the article notes an anomalous consensus full-year EPS figure of ($1,762.50).
• Analyst sentiment is mixed—two Buy ratings and one Sell—leaving a consensus rating of "Hold" and a consensus price target of $70.00 despite the stock trading around $19.75.
• Tonix reported Q3 EPS of ($3.59) matching estimates with revenue of $3.29M (ahead of $2.30M expected), the company has a market cap of $232.66M and institutional ownership of about 82.26% after several hedge funds substantially increased stakes.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap raised their FY2025 earnings per share estimates for Tonix Pharmaceuticals in a report issued on Monday, December 8th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($13.20) for the year, up from their previous estimate of ($14.01). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q4 2025 earnings at ($2.98) EPS, FY2026 earnings at ($6.78) EPS and FY2027 earnings at ($1.08) EPS.

Several other equities research analysts also recently commented on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $70.00.

Tonix Pharmaceuticals Stock Up 0.8%

NASDAQ:TNXP opened at $19.75 on Thursday. The stock has a market capitalization of $232.66 million, a price-to-earnings ratio of -0.98 and a beta of 1.82. Tonix Pharmaceuticals has a 52 week low of $6.76 and a 52 week high of $130.00. The firm has a 50 day moving average of $18.53 and a 200 day moving average of $30.32.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($3.59). Tonix Pharmaceuticals had a negative net margin of 963.39% and a negative return on equity of 55.19%. The company had revenue of $3.29 million for the quarter, compared to analysts' expectations of $2.30 million.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Tonix Pharmaceuticals by 238.1% in the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company's stock valued at $13,456,000 after purchasing an additional 392,225 shares during the period. Geode Capital Management LLC boosted its stake in shares of Tonix Pharmaceuticals by 182.4% in the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company's stock valued at $6,305,000 after purchasing an additional 113,175 shares during the period. Capital Fund Management S.A. purchased a new stake in Tonix Pharmaceuticals during the 3rd quarter worth approximately $1,521,000. Millennium Management LLC boosted its position in Tonix Pharmaceuticals by 494.0% in the 3rd quarter. Millennium Management LLC now owns 52,731 shares of the company's stock valued at $1,274,000 after buying an additional 43,854 shares during the period. Finally, UBS Group AG raised its stake in shares of Tonix Pharmaceuticals by 129.6% in the third quarter. UBS Group AG now owns 51,581 shares of the company's stock valued at $1,246,000 after acquiring an additional 29,118 shares in the last quarter. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.